- Neuroendocrine Cancer
- Newly Diagnosed
- Carcinoid & Neuroendocrine Tumor Patient Community
- Doctor Database
- Clinical Trials
- Educational Resources
- Additional Resources
- Join Us For a Cure
- Research Funding Opportunities
- Current Research Grants
- Previous Research Grants
- Research Approach
- Board of Scientific Advisors
- Research Results
- About Us
Cure Carcinoid Golf Tournament a Success!
Wednesday, October 3, 2012 - 13:26
On Monday, September 24th , CFCF once again proudly supported the annual Cure Carcinoid Golf Tournament in memory of Bradford Monks. Born and raised in Michigan, Brad was a big sports fan who was particularly passionate about golf. After receiving his BA from Duke University and a law degree from Vanderbilt, Brad moved to New York City to pursue his law career at Orrick, Herrington and Sutcliffe. The entrepreneurial spirit within him emerged a few years later when he collaborated with Barry Silbert to found the start-up company Restricted Stock Partners (now Second Market). Just as the business was gaining exciting momentum, Brad received a carcinoid diagnosis. After connecting with CFCF, Brad became incredibly invested in the carcinoid cause, and held a fundraiser that raised over $6,000 for CFCF.
He passed away a year and a half later in 2007, just after his 40th birthday. The final months of Brad's life were marked by the loving support of his close friends, family and the CFCF community. Since golf was Brad's true passion until the very end of his life, his close friends at Second Market suggested holding a golf tournament in Brad's memory. Now in its 6th year, the Cure Carcinoid golf tournament has become an important way to honor Brad's life and commitment to helping others who suffer from the disease.
Last year's tournament was a huge success, raising $50,000 in memory of Bradford Monks. Over the last years, a growing community of supporters has hit the links to raise much-needed funds to fight this deadly disease. All proceeds go to the SecondMarket-Bradford Monks Memorial Award to support cutting-edge neuroendocrine cancer research.